MediPharm Labs Report sees Quarterly Revenue Drop 25%

This morning MediPharm Labs (TSX: LABS) released their fourth quarter results for the year ended December 31, 2019. The quarter saw revenues decline approximately 25.4% from the previous quarter with a 73.6% decline in Adjusted EBITDA over the same period.

The previously beloved cannabis market darling saw a decline in pretty much everything on a quarterly basis:

Q4 2019Q3 2019% Change
Cash $  38,627  $   42,116 -8.3%
Inventory $  51,486  $   54,086 -4.8%
Receivables $  27,540  $   40,756 -32.4%
Accounts Payable $  20,946  $   41,704 -49.8%
Revenue $  32,444  $   43,486 -25.4%
Gross Profit $    9,987  $   14,754 -32.3%
Net Income (pre Tax) $  (2,401) $      5,395 -144.5%
Adjusted EBITDA $    2,661  $   10,066 -73.6%
Operating Cash Flow $  14,100  $   17,069 -17.4%
Investing Cash Flow $  (2,182) $ (10,799)-79.8%

The company cited oversupply of bulk extract, reduction in selling price, lower volumes, slower rollout of cannabis 2.0, slower rollout of retail and lastly a slower rollout of bigger companies entering the space.


The Company reported that the Canadian cannabis sector experienced significant challenges in the fourth quarter that resulted in an oversupply of bulk extract in the market and subsequent reduction in selling price and lower volumes. These factors included: a slower than anticipated expansion of retail channels in Canada, slower licensing of new and specialized cannabis 2.0 businesses, lower than expected conversion of bulk extract inventory into finished goods by vertically integrated players and slower than expected entry to the market by larger consumer packaged goods and pharmaceutical companies.


The company informed shareholders the manufacturing facility was exempted from the recent provincial mandated workplace closures as an essential service. But the company sees some issues with the supply chain potentially breaking down.

At the time of publishing MedipPharm Labs is down 14.65% to $1.69.


Information for this briefing was found via Sedar and MediPharm Labs. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Silver’s Finally Breaking the System | Keith Neumeyer – First Majestic

The Best News for Gold Was the Drop! – Peter Grandich

McEwen Copper: The Los Azules Feasibility Study

Recommended

Steadright To Conduct Multi-Phased Exploration At Historic Goundafa Polymetallic Mine

Goliath Resources Drills 10.72 g/t Gold Over 7.83 Metres At Surebet

Related News

Medipharm Labs Sells Off Australian Assets

MediPharm Labs (TSX: LABS) appears to be slowly pulling back on its international endeavours. The...

Monday, July 11, 2022, 08:11:52 AM

Medipharm Signs Danish White Label Agreement

Medipharm Labs (TSX: LABS) continues to expand its international presence, this morning announcing that it...

Friday, September 25, 2020, 08:49:28 AM

Medipharm Labs Posts Revenues of $13.9 Million, Net Loss of $3.5 Million For Q2 2020

Medipharm Labs (TSX: LABS) reported further disappointing quarterly results this morning, with revenues of $13.9...

Thursday, August 13, 2020, 09:25:18 AM

Medipharm Labs Receives Price Target Reduction From Canaccord To $1.75

Yesterday, On November 16th, Medipharm Labs (TSX: LABS) reported their third quarter financial results. Reported...

Tuesday, November 17, 2020, 03:37:00 PM

Champignon Brands Appoints Medipharm Labs CEO Pat McCutcheon to Board

This morning Champignon Brands Inc. (CSE: SHRM) announced the appointment of Pat McCutcheon to its...

Wednesday, May 6, 2020, 09:18:25 AM